# Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7).

> PubMed lists PMID 30762290 in Diabetes, obesity & metabolism as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-03-29 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30762290-dulaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-05-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30762290-dulaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-30762290-dulaglutide-v1.json
- Content SHA-256: `caeddd77f187545e10a83c0894ee9107dcd14127f35e4730b0320a5982de235b`

## Claims and source pins

### Headline

Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7). ([`pubmed-observation-pmid-30762290-2020-05-29-1c7854c801b8`](#source-pubmed-observation-pmid-30762290-2020-05-29-1c7854c801b8))

### Summary

PubMed lists PMID 30762290 in Diabetes, obesity & metabolism as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-03-29 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30762290-2020-05-29-1c7854c801b8`](#source-pubmed-observation-pmid-30762290-2020-05-29-1c7854c801b8))

### Paragraph 1

PubMed lists PMID 30762290 in Diabetes, obesity & metabolism as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-03-29 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30762290-2020-05-29-1c7854c801b8`](#source-pubmed-observation-pmid-30762290-2020-05-29-1c7854c801b8))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30762290-2020-05-29-1c7854c801b8`](#source-pubmed-observation-pmid-30762290-2020-05-29-1c7854c801b8))

## Sources

<a id="source-pubmed-observation-pmid-30762290-2020-05-29-1c7854c801b8"></a>
- **Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7). · retained source version 1:2020-05-29:current:1c7854c801b85a2d6efcac8400f97f59d891b78cb8dd4221d078c139ceccb7e1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30762290/) (`pubmed-observation-pmid-30762290-2020-05-29-1c7854c801b8`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-30762290-dulaglutide-v1.json SHA-256: caeddd77f187545e10a83c0894ee9107dcd14127f35e4730b0320a5982de235b.